Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Ocular Therapeutix Inc (OCUL)
:OCUL
RESEARCH TOOLSreports
Holding OCUL?
Track your performance easily
Earnings Data
Report Date
Mar 06, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-0.25Last Year’s EPS
-0.35Same Quarter Last Year
Strong Buy
Based on 7 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 07, 2018
|% Change Since: -24.06%
|Next Earnings Date:Aug 07, 2018
Earnings Call Sentiment|Positive
The earnings call was predominantly positive, highlighting significant progress in clinical trial enrollment, strong demand for AXPAXLI, and a solid financial position. The only notable concern was the need for both SOL-1 and SOL-R data for regulatory submission, which may impact timelines. Overall, the outlook is promising, especially with the continued success of DEXTENZA and the anticipation of strong results from the AXPAXLI trials.Company Guidance
During the Ocular Therapeutix Third Quarter 2024 Earnings Conference Call, key guidance metrics were shared, highlighting the progress and future expectations for their clinical trials. The company achieved a significant milestone with the SOL-1 trial, reaching full randomization ahead of schedule and enabling direct patient enrollment into the SOL-R trial. This advancement is expected to accelerate SOL-R's enrollment pace. The company projects the SOL-1 trial to complete randomization by the end of 2024, with topline data anticipated in the fourth quarter of 2025. Financially, Ocular Therapeutix reported cash and cash equivalents of approximately $427 million, providing operational runway into 2028, which includes full funding for the SOL-1 and SOL-R trials. Additionally, the company is preparing for a strong commercial launch of AXPAXLI, should it be approved, leveraging the success of their existing product, DEXTENZA, and expanding their commercial infrastructure.Successful SOL-1 Enrollment
SOL-1 recruitment progressed rapidly, allowing full randomization ahead of prior guidance. This milestone enables direct enrollment into SOL-R, the second registrational trial for AXPAXLI in wet AMD, further accelerating its pace.
Positive Engagement in Clinical Trials
There is outstanding demand for participation in AXPAXLI clinical studies, indicating strong enthusiasm within the retina community for a durable treatment option.
Potential Superiority and Differentiation of AXPAXLI
AXPAXLI showed a 100% per protocol rescue-free rate at 6 months in a prior U.S. wet AMD study and significant efficacy in nonproliferative diabetic retinopathy. The trials are designed to provide potentially superior and differentiated results compared to existing treatments.
Strong Financial Position
Ocular Therapeutix reported approximately $427 million in cash and cash equivalents at the end of the third quarter, providing a financial runway into 2028 and fully funding SOL-1 and SOL-R to top line results.
Continued Success with DEXTENZA
The commercial team is achieving excellent results with DEXTENZA, which strengthens market presence and provides a strategic edge for the launch of AXPAXLI.
---
OCUL Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
OCUL Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 14, 2024 | $10.60 | $9.92 | -6.42% |
| Aug 07, 2024 | $7.89 | $8.37 | +6.08% |
| May 07, 2024 | $5.93 | $5.75 | -3.04% |
| Mar 11, 2024 | $9.73 | $9.29 | -4.52% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Ocular Therapeutix Inc (OCUL) report earnings?
Ocular Therapeutix Inc (OCUL) is schdueled to report earning on Mar 06, 2025, TBA Not Confirmed.
What is Ocular Therapeutix Inc (OCUL) earnings time?
Ocular Therapeutix Inc (OCUL) earnings time is at Mar 06, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is OCUL EPS forecast?
OCUL EPS forecast for the fiscal quarter 2024 (Q4) is -0.25.
---